Key PointsOne of CRISPR Therapeutics’ leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.